Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)
CompletedPhase 2NCT00667654
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will evaluate dosing regimens of 4975 in terms of safety and tolerability when delivered as an intra-articular injection in the knee. Secondary objectives will be to explore the efficacy of 4975 in terms of onset, extent and duration of pain relief.
Study details
- Official title
- A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis
- Conditions
- Interventions
- Drug: CNTX-4975
- Sponsor
- Centrexion Therapeutics
- Start date
- 2007-08
- Primary completion
- 2008-06
- Sex
- All
- Age range
- from 40 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female patients aged 40 years or over. * Body mass index (BMI) of 35 or less. * History of OA of the knee for at least 1 year and has experienced pain in the target area for at least six months. * X-Ray of the target knee. * Willing and able to complete the study procedures. Exclusion Criteria: * Female patients who are pregnant or lactating or who plan to get pregnant. * Clinically significant form of joint disease other than OA. * Medical condition that could adversely impact the patient's participation, safety or affect the conduct of the study. * Prior major trauma in the target knee or major surgeries such as partial or total knee arthroplasty. * Arthroscopic surgery on the target knee within 6 months.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00667654